Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v2.4.0.8
Condensed Consolidated Balance Sheets (USD $)
In Thousands, unless otherwise specified
Sep. 30, 2014
Dec. 31, 2013
Current assets:    
Cash and cash equivalents $ 11,240 $ 7,279
Marketable securities, current 56,505 58,390
Collaboration receivable 4,463 18,094
Prepaid expenses and other current assets 1,888 2,246
Total current assets 74,096 86,009
Marketable securities, non-current 778 16,364
Property and equipment, net 637 686
Other assets 1,159 1,059
Total assets 76,670 104,118
Current liabilities:    
Accounts payable 3,414 1,689
Accrued clinical and development expenses 4,142 7,444
Accrued liabilities 2,697 3,161
Deferred revenue, current 14,722 14,722
Total current liabilities 24,975 27,016
Warrant liability 6,564 23,421
Deferred revenue, non-current 65,874 76,916
Deferred rent 260 240
Total liabilities 97,673 127,593
Commitments and contingencies (Note 7)      
Stockholders’ equity (deficit):    
Preferred stock, $0.001 par value, 2,000,000 shares authorized; no shares issued and outstanding      
Common stock, $0.001 par value, shares authorized: 150,000,000 shares; issued and outstanding: 62,436,865 shares at September 30, 2014 and 59,232,611 shares at December 31, 2013 62 59
Additional paid-in capital 346,229 328,116
Accumulated other comprehensive gain (loss) 4 28
Accumulated deficit (367,298) (351,678)
Total stockholders’ equity (deficit) (21,003) (23,475)
Total liabilities and stockholders’ equity (deficit) $ 76,670 $ 104,118